ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
17.932,17
-1,10%
S&P 500
5.018,39
-0,34%
Dow Jones
37.903,29
0,23%
Euro vs US Dollar
1,07205
0,03%
Bitcoin
57.336,47
-1,54%
Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Corcept Therapeutics Inc (CORT)

  7. Corcept Therapeutics Inc (CORT) News

CORT Corcept Therapeutics Inc

26,90
3,58 (15,35%)
02 Mai 2024 - Geschlossen
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Corcept Therapeutics Inc CORT NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
Upgrade Icon
3,58 15,35% 26,90 01:57:49
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
23,09 22,60 24,61 23,88 23,32
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
01.5.202422:05GLOBECorcept Therapeutics Announces First Quarter Financial..
29.4.202414:00GLOBECorcept Completes Enrollment in Phase 4 CATALYST Trial
24.4.202422:05GLOBECorcept Therapeutics to Announce First Quarter Financial..
22.4.202414:00GLOBECorcept Announces Positive Results From Open-Label Portion..
15.4.202414:00GLOBECorcept Completes Enrollment in Phase 2 DAZALS Trial in..
08.4.202414:00GLOBECorcept Completes Enrollment in Pivotal Phase 3 Rosella..
01.4.202414:00GLOBECorcept Completes Enrollment in Phase 3 Gradient Trial of..
06.3.202403:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06.3.202403:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06.3.202403:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06.3.202403:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06.3.202403:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06.3.202402:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01.3.202423:24EDGAR2Form 144 - Report of proposed sale of securities
22.2.202403:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21.2.202402:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16.2.202418:12EDGAR2Form 144 - Report of proposed sale of securities
15.2.202422:17EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
15.2.202422:11EDGAR2Form 8-K - Current report
15.2.202422:07GLOBECorcept Therapeutics Announces Fourth Quarter and Full-Year..
15.2.202422:02GLOBECorcept Announces Preliminary Results From Prevalence Phase..
15.2.202421:45EDGAR2Form 144 - Report of proposed sale of securities
14.2.202422:23EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14.2.202402:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14.2.202402:25EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14.2.202402:20EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14.2.202402:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14.2.202401:59EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14.2.202401:40EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14.2.202401:38EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13.2.202422:46EDGAR2Form 5 - Annual statement of changes in beneficial ownership..
13.2.202401:51EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
08.2.202422:05GLOBECorcept Therapeutics to Announce Fourth Quarter and..
02.2.202423:39EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01.2.202420:17EDGAR2Form 144 - Report of proposed sale of securities
29.1.202414:00GLOBECorcept Appoints Roberto Vieira as President, Oncology
22.1.202421:52EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
13.1.202402:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08.1.202414:06EDGAR2Form 8-K - Current report
08.1.202414:00GLOBECorcept Therapeutics Provides Financial Update and Announces..
05.1.202401:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02.1.202417:24EDGAR2Form 144 - Report of proposed sale of securities
02.1.202414:06EDGAR2Form 8-K - Current report
02.1.202414:00GLOBECourt Finds Corcept Therapeutics’ Patents Not Infringed
23.12.202301:29EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22.12.202318:09EDGAR2Form 144 - Report of proposed sale of securities
20.12.202300:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16.12.202303:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13.12.202302:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11.12.202322:34EDGAR2Form 8-K - Current report

Kürzlich von Ihnen besucht

NASDAQ
CORT
Corcept Therapeutics
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten